Cannabis-Like drugs may unlock diabetes secrets
NCT ID NCT01517100
First seen Jun 24, 2026 · Last updated Sep 09, 2026 · Updated 12 times
Summary
This study tested two drugs that act on the body's endocannabinoid system—nabilone and CP-945,598—to see how they affect insulin production and sensitivity. Forty-five healthy men aged 21 to 55 took part in four visits, each receiving a different drug combination. The goal was to better understand how this system regulates insulin, which could lead to new diabetes treatments.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Nabilone and CP-945,598
- What this could lead to
- If successful, this could point toward new treatment approaches for type 2 diabetes by targeting the endocannabinoid system.
- What could go wrong
- This is a small, early-phase study in healthy men, not people with diabetes. Results may not translate to real-world treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
45 people
The number who actually took part.
- Start date
-
Jan 2012
- Finished
-
Oct 2014
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: 1. Healthy men only (We want to study men because the magnitude of acute insulin response for men and women is different. In addition, as women may become pregnant in the course of the study, and since this is a physiology study only, and not one related to treatments, we want to remove any confounders and lessen any chance of drop-out.) 2. Age 21-55 (Age restriction is used to remove age as a confounding factor because Beta cells function tends to deteriorate and first phase secretion becomes less defined with age. 3. Screening laboratory evaluations with no clinically significant abnormal results (minor deviations from normal lab results will be at the discretion of the principal investigator): 1. fasting comprehensive metabolic panel 2. complete blood count with differential and platelet 3. thyroid function test (TSH, free T4) 4. urinalysis 5. urine drug screen 4. BMI less than 30 (Men with BMI greater than or equal to 30 are excluded because obesity has been associated with altered beta cell function. 5. Have NOT participated in another clinical trial involving any pharmacologic agents within the past 30 days 6. Able to complete an inform consent 7. Agree to not participate in other clinical trials within the study period (at the discretion of the study investigator) EXCLUSION CRITERIA: 1. Women 2. FPG greater than or equal to 100 mg/dl or 2-hr OGTT greater than or equal to 140 mg/dL 3. Evidence of illicit drug use 4. History of substance abuse including marijuana within the past 6 months 5. History of smoking any tobacco products within six months prior to screening 6. Alcohol intake greater than 30 grams (drink more than 2 beers per day OR equivalent amount of alcohol) 7. History of Human Immunodeficiency Virus (HIV) infection 8. History of active or chronic Hepatitis B and/or C infection 9. History of malignancy 10. History of coronary disease 11. History of seizures or other neurologic diseases 12. History of psychiatric illnesses including major depressive disorder, schizophrenia, bipolar disorder 13. Any lifetime history of suicide attempt 14. History of suicidal behavior in the last year 15. Any suicidal behavior during any follow-up visits 16. History of any suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the last year 17. Any suicidal ideation of type 4 or 5 on the C-SSRS during any follow-up visits. 18. Patient Health Questionnaire-9 (PHQ-9) score greater than or equal to 10 during screening visit or any follow-up study visits 19. Generalized Anxiety Disorder-7 (GAD-7) score greater than or equal to 10 during screening visit or any follow-up visits 20. History of liver or renal diseases 21. History of gastrointestinal or endocrine disorders 22. History of glucocorticoid use (over one month) or other immunosuppressive agents (any) 23. Any condition or non-removable device contraindicated for MRI (pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips, metallic prostheses, permanent eyeliner, implanted delivery pump, or shrapnel fragments, or history of working as a welders or metal worker) 24. Any medical history that, in the opinion of the investigator(s), will make participation of the subject in the study unsafe
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institute of Aging, Clinical Research Unit
Baltimore, Maryland, 21224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe the nerve highways behind strength gains
- New syphilis test kits put to the test with donated blood
- Can a copy of a blockbuster arthritis drug match the original? scientists test it in healthy people
- Novo nordisk tests Brand-New molecule in humans for the first time
- New sedative candidate goes Head-to-Head with propofol in early human test
- Can a Room-Temperature dairy drink build muscle?